Today's Daily Dose brings you news about the approval of the world's first device for treatment of premature babies and newborns with an opening in their hearts; the impact of the U.S. government shutdown on Aimmune Therapeutics; Array's BEACON CRC trial results; and Exelixis' expanded FDA approval for Cabometyx tablets.
from RTT - Biotech http://bit.ly/2FwxaDI
via IFTTT
No comments:
Post a Comment